GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 BusinessWire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on GLYC
    GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
    7:00a ET April 25 '24 BusinessWire

    GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.

    To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.

    A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.

    About GlycoMimetics, Inc.

    GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company's scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. GlycoMimetics is leveraging its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company's goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240425404134/en/

    SOURCE: GlycoMimetics, Inc.

    <img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240425404134r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

    Investor Contact: 
    Argot Partners
    Leo Vartorella
    212-600-1902
    Glycomimetics@argotpartners.com
    

    COMTEX_451392257/1006/2024-04-25T07:00:01

    GlycoMimetics Reports Highlights and Financial Results for Fourth Qua...
    7:00a ET March 27 '24 BusinessWire
    GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial R...
    7:00a ET March 13 '24 BusinessWire
    GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Car...
    7:00a ET February 26 '24 BusinessWire
    GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635...
    7:00a ET February 12 '24 BusinessWire

    Market data provided by News provided by